Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720185 · ClinicalTrials.gov registry record · Phase 2
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02720185: Clinical Trial Phase 2 study, sponsored by University of Wisconsin, Madison.
NCT02720185 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02720185, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety and tolerability of dasatinib in patients with operable TNBC 2. To explore potential intracellular mechanisms which impact dasatinib effect on cellular localization of EGFR in operable TNBC. 3. To examine the pathologic complete response (pCR) rates to standard neoadjuvant chemotherapy in nEGFR+ TNBC 4. To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+ TNBC
Primary Outcome
An increase of at least 25% from baseline to post-dasatinib treatment will be considered significant. VECTRA is an automated pathology imaging system used to detect biomarkers in samples.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Dasatinib
- PROCEDURE Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 2 |
Why NCT02720185 stopped before completion
NCT02720185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02720185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02720185 about?
NCT02720185 is a clinical study titled "Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR". Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety a...
What is the current status of trial NCT02720185?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-05-03. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT02720185?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dasatinib (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02720185?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02720185's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI